Identifying KL-6-Associated Immune Cell Signatures and Key Genes in Emphysematous COPD
Open Access
- 1 May 2025
- journal article
- research article
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 6453-6466
Abstract
Background: This study aimed to evaluate the potential of Krebs von den lungen-6 (KL-6) as a biomarker for distinguishing emphysematous chronic obstructive pulmonary disease (COPD-E) from non-emphysematous COPD (COPD-NE), and to explore the underlying mechanisms associated with KL-6 expression. Methods: We enrolled 154 patients with COPD and 170 healthy controls to assess serum KL-6 levels. Receiver operating characteristic curve was used to determine the diagnostic sensitivity and specificity. Pearson’s correlation analysis was used to evaluate the correlation. Univariate and multivariate linear regression analyses were performed to explore the factors influencing KL-6 levels in COPD. Transcriptomic sequencing was performed on peripheral blood mononuclear cells from COPD patients with varying KL-6 levels to explore underlying biological mechanisms. A Mendelian randomization analysis was employed to ascertain the association between the expression quantitative trait loci of key genes and emphysema risk. Results: Serum KL-6 levels were significantly elevated in COPD patients, particularly in COPD-E. Pearson analyses revealed that the serum KL-6 concentration was positively correlated with eosinophil count. Transcriptomic analysis revealed 237 differentially expressed genes (DEGs) between patients with high and low levels of KL-6. Gene set enrichment analysis revealed that these DEGs were associated with immune responses. No significant difference in immune cell proportions were observed between high and low KL-6 groups, but KL-6 showed a negative correlation with T cell gamma delta. By intersecting the DEGs with those from the GSE248493 dataset, we identified seven key genes and further validated their association with the risk of emphysema using Mendelian randomization, with amidohydrolase domain containing 2 (AMDHD2) potentially reducing the risk of the disease. Conclusion: KL-6 is a promising biomarker for distinguishing COPD-E from COPD-NE and AMDHD2 may be involved in the regulation of increased KL-6 levels in COPD-E.Keywords
This publication has 43 references indexed in Scilit:
- Associations of the Serum KL-6 with Severity and Prognosis in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary DiseaseLung, 2024
- The hexosamine biosynthetic pathway and cancer: Current knowledge and future therapeutic strategiesCancer Letters, 2021
- Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive PhenotypeChest, 2020
- Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017The Lancet, 2019
- Changes in serum KL-6 levels are associated with the development of chronic lung allograft dysfunction in lung transplant recipientsTransplant Immunology, 2019
- Chronic obstructive pulmonary disease subpopulations and phenotypingJournal of Allergy and Clinical Immunology, 2018
- Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary diseaseJournal of Allergy and Clinical Immunology, 2018
- New Anti-Eosinophil Drugs for Asthma and COPDChest, 2017
- A novel lung injury animal model using KL-6-measurable human MUC1-expressing miceBiochemical and Biophysical Research Communications, 2013
- THE EMPHYSEMATOUS AND BRONCHIAL TYPES OF CHRONIC AIRWAYS OBSTRUCTIONThe Lancet, 1966